Pathway Medical Technologies Receives FDA 510(K) Clearance for Jetstream G2 System

New Technology Delivers Highly Effective, Minimally Invasive Treatment for Entire Spectrum of Peripheral Artery Disease

KIRKLAND, Wash.--(HSMN NewsFeed)--Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral arterial disease (PAD), today announced that the U.S. Food & Drug Administration (FDA) has granted the company 510(k) clearance to market its newest peripheral atherectomy catheter for use in the treatment of PAD in the lower limbs. Jetstream G2™ is the latest technology innovation from Pathway and is capable of treating the entire spectrum of disease found in the PAD patient, including hard and soft plaque, calcium, thrombus and fibrotic lesions, with consistent results.

“Jetstream took conventional atherectomy procedures to the next level, enabling physicians to remove all types of both hard and soft tissue plaque with a single device and greatly improving the way patients are treated for peripheral artery disease,” said Pathway Medical Technologies President and CEO Paul Buckman, “Jetstream G2 is a major milestone for the company and the industry, and we firmly believe that this enhanced technology will significantly increase the number of PAD sufferers for whom atherectomy is a viable treatment option. Today’s news further underscores and validates Pathway’s continued commitment to delivering innovative technologies for the minimally invasive treatment of a condition that affects millions of people across the U.S.”

Full text >>